Richards Merrill & Peterson Inc. Buys 156 Shares of Eli Lilly and Company $LLY

Richards Merrill & Peterson Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 25.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 767 shares of the company’s stock after purchasing an additional 156 shares during the quarter. Richards Merrill & Peterson Inc.’s holdings in Eli Lilly and Company were worth $598,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Hobbs Wealth Management LLC boosted its stake in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after buying an additional 12 shares during the period. Hixon Zuercher LLC lifted its position in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock worth $1,477,000 after buying an additional 12 shares during the last quarter. O Brien Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after acquiring an additional 12 shares during the last quarter. Ascent Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after buying an additional 12 shares during the period. Finally, Willner & Heller LLC grew its holdings in shares of Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after purchasing an additional 13 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LLY shares. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Guggenheim reissued a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Trading Up 0.6%

Shares of LLY opened at $825.86 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company’s fifty day moving average is $768.01 and its 200 day moving average is $768.14. The stock has a market capitalization of $781.65 billion, a PE ratio of 53.98, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the company posted $3.92 EPS. The business’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.